Editorial: anemia management with erythropoiesis-stimulating agents: a risk-benefit update.
Aapro
Matti S
MS
D000740:Anemia / Q000139:chemically induced / Q000188:drug therapy*; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D004921:Erythropoietin / Q000627:therapeutic use*; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy; D011994:Recombinant Proteins; D018570:Risk Assessment; D013923:Thromboembolism / Q000139:chemically induced
D000970:Antineoplastic Agents; D006454:Hemoglobins; D011994:Recombinant Proteins; D004921:Erythropoietin